Muhamad Alhaj Moustafa, MD, MS, discusses the phase 3 SHINE trial, which evaluated ibrutinib given with bendamustine and rituximab in patients with mantle cell lymphoma.
Muhamad Alhaj Moustafa, MD, MS, has improved the treatment of patients with mantle cell lymphoma, and the role that this agent has in the current treatment landscape.